The effect of antithrombin on pulmonary endothelial damage induced by crush injury.
After crush injury, patients often experience multiple organ dysfunction syndrome. In this study, we focused on vascular endothelial damage, which is believed to be a possible cause of multiple organ dysfunction syndrome, and revealed a pathological condition of distant organ failure. In particular, the lung is an especially prone target organ at the time of systemic inflammatory invasion after crush injury. We ascertained the effect of antithrombin (AT), which has recently attracted attention for its endothelial protective effects. Using a rat model of crush syndrome, we assessed severity of systemic inflammation and vascular endothelial damage through a blood test and degree of lung injury and centrally focused on morphological analysis of endothelium over time. Crush injury significantly elevated the blood concentration of tissue plasminogen activator-plasminogen activator inhibitor 1 complex, monocyte chemoattractant protein 1, and IL-6. Accumulation of active inflammatory cells (OX-42-positive cells) and expression of von Willebrand factor and vascular cell adhesion molecule 1 significantly increased in the lung 24 h after releasing crush. After 48 h, disarray of alveolar structure and alveolar hemorrhage appeared. Antithrombin administration significantly suppressed accumulation of inflammatory cells, expression of von Willebrand factor and vascular cell adhesion molecule 1, and mortality rate. Our research demonstrates that crush injury induces acute lung injury as distant organ failure, and it would seem that AT administration diminishes vascular endothelial damage and is effective against crush injury.
Sonoi
Hideaki
H
Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan. sonoi@hp-emerg.med.osaka-u.ac.jp
Matsumoto
Naoya
N
Ogura
Hiroshi
H
Hosotsubo
Hideo
H
Noguchi
Kazuo
K
Kuwagata
Yasuyuki
Y
Sugimoto
Hisashi
H
D000818:Animals; D000991:Antithrombins / Q000378:metabolism*; D001777:Blood Coagulation; D018932:Chemokine CCL2 / Q000096:biosynthesis; D003444:Crush Syndrome / Q000378:metabolism*; D004730:Endothelium, Vascular / Q000166:cytology*; D007249:Inflammation; D015850:Interleukin-6 / Q000096:biosynthesis; D008168:Lung / Q000378:metabolism*; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000096:biosynthesis; D016896:Treatment Outcome
D000991:Antithrombins; C491766:Ccl2 protein, rat; D018932:Chemokine CCL2; D015850:Interleukin-6; D010959:Tissue Plasminogen Activator